13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • CA209-914

    Acronym: 

    Checkmate 914

    ACTRN/NCT /ethics: 

    NCT03138512

    Scientific title: 

    A study comparing the combination of nivolumab and ipilimumab versus placebo in participants with localized renal cell carcinoma

    Summary of trial and patient characteristics

    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase III Tumour Stream Renal cell carcinoma
    Age Range 18 years and older Cancer Stage In Situ
    Sex Both Anticipated Start Date 2017-07-05
    Molecular Target Anticipated End Date 2023-07-07
    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Renal cell carcinoma
    Cancer Stage In Situ
    Anticipated Start Date 2017-07-05
    Anticipated End Date 2023-07-07

    Trial Summary

    A phase 3 randomised study comparing nivolumab and ipilimumab combination versus placebo in participants with localized renal cell carcinoma who underwent radical or partial nephectomy and who are at high risk of relapse

    Lay Summary

    A study comparing the combination of nivolumab and ipilimumab versus placebo in participants with localized renal cell carcinoma

    Sponsor / Cooperative group

    Bristal-Myers Squibb

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Lyell McEwin Hospital Andy Phay andy.phay@sa.gov.au 08 8282 0833 Dr Christopher Hocking Recruiting